Skip to main content

Phase 3 Start

ANVS: Phase3_Start: An Open-label Clinical Trial Investigating the Long-term Safety of Buntanetap in Treating Participants With Alzheimer's Disease

September 21, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date
September 21, 2026
Company
Annovis Bio, Inc. (ANVS)
BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Start

Phase3_Start: An Open-label Clinical Trial Investigating the Long-term Safety of Buntanetap in Treating Participants With Alzheimer's Disease